KLN205 Syngeneic Model Overview
The KLN205 syngeneic model is a murine squamous cell carcinoma system derived from a spontaneous pulmonary lesion in DBA/2 mice. It serves as a well-characterized and reproducible preclinical platform for studying non-keratinizing squamous carcinoma within an immunocompetent environment. This model exhibits moderate growth kinetics, well-defined histopathology, and partial responsiveness to immunotherapeutic agents, making it particularly valuable for evaluating immune checkpoint blockade, cytokine modulation, and tumor–immune cell interactions in squamous epithelial malignancies.
When implanted subcutaneously or orthotopically into DBA/2 mice, KLN205 tumors demonstrate consistent take rates and reproducible growth curves. The model’s immunocompetent host background enables comprehensive assessment of immune infiltration, stromal remodeling, and tumor-induced immune suppression. Because squamous carcinomas represent a distinct histological and immunological category compared with adenocarcinomas, the KLN205 model has become a critical system for testing therapeutic interventions specifically targeting squamous cell biology, including head and neck, pulmonary, and cutaneous squamous carcinomas.
Request a Custom Quote for KLN205 Syngeneic ModelBiological and Molecular Characteristics
The KLN205 cell line was established from a spontaneous pulmonary squamous carcinoma in DBA/2 mice and exhibits epithelial morphology with cohesive, polygonal cells and keratinization foci. The tumors display a moderate proliferation rate and generate compact, well-demarcated nodules with limited spontaneous metastasis. Molecular analysis indicates high expression of keratin-associated proteins and adhesion molecules characteristic of squamous epithelial differentiation.
The tumor microenvironment includes macrophages, neutrophils, and T lymphocytes distributed throughout the stroma and peritumoral regions. Cytokine analysis of KLN205 tumors shows upregulation of IL-6, TNF-α, and CXCL1, consistent with a pro-inflammatory yet partially immunosuppressive profile. The combination of epithelial differentiation and active immune involvement makes this model suitable for preclinical studies focused on immune–epithelial signaling, checkpoint inhibition, and tumor immunomodulation.
| Parameter | Description |
|---|---|
| Host strain | DBA/2 (female, 6–8 weeks) |
| Tumor origin | Spontaneous pulmonary squamous cell carcinoma (mouse) |
| Histological type | Non-keratinizing squamous carcinoma |
| Inoculation route | Subcutaneous, orthotopic, or intravenous |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–5 days in vivo |
| Metastatic potential | Low; localized primary growth |
| Immunophenotype | Moderate T-cell infiltration; macrophage-rich microenvironment |
| Common applications | Squamous carcinoma, immunotherapy, checkpoint inhibition, cytokine studies |
In Vivo Model Development and Tumorigenicity
In vivo establishment of the KLN205 syngeneic model is typically achieved through subcutaneous implantation of viable tumor cells into DBA/2 mice, resulting in consistent tumor formation within 7–10 days post-inoculation. Orthotopic implantation into the trachea or lung can also be employed to model pulmonary squamous carcinoma and evaluate therapeutic response in a site-relevant microenvironment. Tumor growth is reproducible and generally exhibits a moderate rate, allowing for controlled study duration and comprehensive immunological monitoring.
The KLN205 model is particularly useful for assessing immune checkpoint inhibitors and immunomodulatory therapies that target squamous carcinoma–associated inflammation. Because the DBA/2 host retains a fully functional immune system, the model supports detailed examination of macrophage polarization, T-cell activation, and cytokine dynamics following therapeutic intervention. The balance between tumor immunogenicity and immune suppression makes KLN205 an informative system for mechanistic immuno-oncology studies.
Request a Custom Quote for KLN205 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological evaluation of KLN205 tumors reveals well-differentiated squamous epithelial architecture with areas of keratinization, intercellular bridges, and localized necrosis. The tumor parenchyma consists of cohesive polygonal cells with eosinophilic cytoplasm, embedded within a fibrous stroma infiltrated by immune and stromal cells. The tumor margins are clearly delineated, and vascularization is moderate, providing efficient perfusion without excessive angiogenic complexity.
Immunohistochemical characterization demonstrates moderate to high Ki-67 expression, indicative of active proliferation. Cytokeratin staining confirms squamous epithelial differentiation, while CD3 and CD8 staining highlight T-cell infiltration at both the peritumoral and intratumoral levels. F4/80 and CD11b staining identify a significant macrophage population contributing to immune regulation within the tumor stroma. PD-L1 expression is detectable on both tumor and infiltrating immune cells, increasing upon interferon exposure or immune checkpoint inhibition. The overall profile of KLN205 tumors supports their classification as moderately immunogenic squamous carcinomas suitable for immune-targeted therapeutic research.
Preclinical Applications and Drug Response
The KLN205 syngeneic model is widely employed for preclinical evaluation of immunotherapies, targeted agents, and radiation-based combination strategies in squamous cell carcinoma. It demonstrates measurable, though variable, responsiveness to checkpoint inhibitors such as anti–PD-1 and anti–CTLA-4 antibodies, accompanied by enhanced CD8⁺ T-cell infiltration and macrophage activation. The model is also suitable for studies investigating the immunologic consequences of cytokine therapy, including interferon and interleukin-based agents.
Combination treatments incorporating immune checkpoint blockade, chemotherapeutics, or radiation have produced additive effects in KLN205-bearing mice, resulting in improved tumor control and evidence of immune priming. Because of its immunocompetent DBA/2 host and squamous epithelial origin, KLN205 provides a biologically relevant framework for studying immune escape, therapeutic synergy, and immune reprogramming in squamous malignancies. Its balanced growth kinetics and reproducible immune microenvironment continue to make it a cornerstone model for immunotherapy and translational oncology research.
Request This Model
To request the KLN205 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for KLN205 Syngeneic Model